Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial.

Pleat, Rebecca; Cox, Timothy M; Burrow, T Andrew; Giraldo, Pilar; Goker-Alpan, Ozlem; Rosenbloom, Barry E; Croal, Laura R; Underhill, Lisa H; Gaemers, Sebastiaan J M; Peterschmitt, M Judith

Pleat, Rebecca; Cox, Timothy M; Burrow, T Andrew; Giraldo, Pilar; Goker-Alpan, Ozlem; Rosenbloom, Barry E; Croal, Laura R; Underhill, Lisa H; Gaemers, Sebastiaan J M; Peterschmitt, M Judith.

Afiliación

Pleat R; Sanofi Genzyme, Cambridge, MA, USA.
Cox TM; Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
Burrow TA; Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Giraldo P; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), IISAragón, Zaragoza, Spain.
Goker-Alpan O; Lysosomal Disorders Research and Treatment Unit, Center for Clinical Trials, O&O Alpan, LLC, Fairfax, VA, USA.
Rosenbloom BE; Cedars-Sinai/Tower Hematology Oncology, Beverly Hills, CA, USA.
Croal LR; Sanofi Genzyme, Cambridge, MA, USA.
Underhill LH; Sanofi Genzyme, Cambridge, MA, USA.
Gaemers SJ; Sanofi Genzyme, Cambridge, MA, USA.
Peterschmitt MJ; Sanofi Genzyme, Cambridge, MA, USA.

Mol Genet Metab Rep ; 9: 25-28, 2016 Dec.

Article en En | MEDLINE | ID: mdl-27722092

Palabras clave

Composite endpoint; Eliglustat; Gaucher disease type 1; Imiglucerase; Non-inferiority trial; Velaglucerase alfa

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Mol Genet Metab Rep Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google